Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: The CLARICOR trial

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 411-415

  Jespersen, C M ^a,b   Kolmos, H J ^c   Frydendall, N ^a   Hilden, J ^d   Gluud, C ^a   Hansen, Fischer J ^b  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adverse reactions; Macrolides; Morbidity; Mortality

Indexed keywords

CLARITHROMYCIN; KLACID UNO; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FLATULENCE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEARTBURN; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NAUSEA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; STOMACH DISEASE; STROKE; TASTE DISORDER; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLARITHROMYCIN; CORONARY DISEASE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS; YOUNG ADULT;

EID: 67650739468     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp190     Document Type: Article

References (10)

1. Hansen S, Als-Nielsen B, Damgaard M et al. Intervention with clarithromycin in patients with stable coronary heart disease: The CLARICOR trial design. Heart Drug 2001; 1:14-9.
2. Gluud C, Als-Nielsen B, Damgaard M et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008; 111: 280-7.
3. Jespersen CM, Als-Nielsen B, Damgaard M et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332: 22-7.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1), 1996. http://www.ich.org/LOB/media/MEDIA482.pdf (22 April 2009, date last accessed).
5. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
6. Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
7. Wood L, Egger M, Gluud LL et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ 2008; 336: 601-5.
8. Clifford K, Huck W, Shan M et al. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann Otol Rhinol Laryngol 1999; 108: 360-7.
9. Lode H, Aronkyto T, Chuchalin AG et al. A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2004; 10: 403-8.
10. U.S. Food and Drug Administration. FDA Alert for Healthcare Professionals: Clarithromycin (in the CLARICOR Study). http://www.fda.gov/cder/drug/InfoSheets/HCP/clarithromycinHCP.pdf (22 April 2009, date last accessed).